2013 issue 3

Back

Volume 22, issue 3

Review article

Vortioxetine – a new option in the treatment of depression and general anxiety disorder

Adam Wysokiński1, Iwona Kłoszewska1
1. Klinika Psychiatrii Dorosłych, II Katedra Chorób Układu Nerwowego, Uniwersytet Medyczny, Łodź
Postępy Psychiatrii i Neurologii 2013; 22(3): 187-192
Keywords: depression, antidepressants, vortioxetine, general anxiety disorder

Abstract

Objectives. The aim of this publication is to present data available on vortioxetine - a new multimodal antidepressant.

Review. Vortioxetine is a new antidepressant of multimodal mechanism of action: inhibitor of serotonin reuptake, agonist of 5-HT1A and 5-HT1B receptors and antagonist of 5-HT3A and 5-HT7 receptors. Results of clinical trials confirm its antidepressant activity while its safety profile is supposed to be better than duloxetine or venlafaxine. Results of trials on its efficacy in the treatment of general anxiety disorder are inconclusive. Vortioxetine safety profile is similar to typical for other SSRI antidepressants.

Conclusions. Available clinical data does not indicate that the drug is more effective than currently available antidepressants. In two studies (in which doses 2.5 and 5 mg were used) no differences versus placebo were found. Moreover, vortioxetine was not evaluated in studies of more than 20 weeks in duration, thus there is no strong evidence that confirms its efficacy and safety in long-term treatment.

Address for correspondence:
Dr n med. Adam Wysokiński
Klinika Psychiatrii Wieku Podeszłego i Zaburzeń Psychotycznych Uniwersytetu Medycznego w Łodzi
ul. Czechosłowacka 8/10, 92-216 Łód
e-mail: adam.wysokinski@gmail.com